· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2023 / N 2 Ведение пациентов с нарушением пуринового обмена: фокус на поражение почек (обзор литературы и собственные данные) В.В Цурко, М.А. Громова, Л.К. Козлова Список литературы/References 1. Малхасян В.А., Семенякин И.В., Иванов В.Ю., Попова А.С. Консервативная терапия уратного литиаза. Обзор литературы. Медицинский совет. 2015;(4):92-95. [Malkhasyan VA, Semenyakin IV, Ivanov VYu, Popova AS. Conservative therapy of urate lithiasis: a review of literature. Medical Council. 2015;(4):92-95. (In Russ.).] DOI: 10.21518/2079-701X-2015-4-92-95 2. Neogi T. Asymptomatic hyperuricemia: cardiovascular and renal implications. In: Gout and other crystal arthropathies. Terkeltaub R, editor. Philadelphia, PA: Saunders Elsevier; 2012: 226-238. 3. Елисеев М.С. Подагра. М.: Гэотар-Медиа; 2019. 237 с. [Yeliseyev MS. Gout. Moscow: Geotar-Media; 2019. 237 p. (In Russ.).] 4. Михайлова З., Михайлова Ю. Подагрическая нефропатия: диагностика, подходы к лечению. Врач. 2018;29(7):6-29. [Mikhailova Z, Mikhailova Yu. Gouty nephropathy: diagnosis, approaches to treatment. Vrach (The Doctor). 2018;29(7):26-29. (In Russ.).] DOI: 10.29296/25877305-2018-07-04 5. Milner Q. Renal disease. Oxford Medicine Online. 2016 Available from: https://doi.org/10.1093/med/9780198719410.003.0006 Accessed 2023 Aug 14. 6. Mei Y, Dong B, Geng Z, Xu L. Excess uric acid induces gouty nephropathy through crystal formation: a review of recent insights. Frontiers in Endocrinology. 2022;13:911968. DOI: 10.3389/fendo.2022.911968 7. Ривкин АМ. Мочекислый диатез – всегда ли это проявление нарушений пуринового обмена. Лечащий врач. 2011;8:45-49. [Rivkin AM. Uric acid diathesis – is it always a manifestation of purine metabolism disorders. Lechashchiy Vrach. 2011;8:45-49. (In Russ.).] 8. Нефрология. Национальное руководство. Под ред. Мухина Н.А. М.: Гэотар-Медиа; 2009. 720 с. [Nephrology. National guidelines. Mukhina NA, editor. Moscow: Geotar-Media; 2009. 720 p. (In Russ.).] 9. Чичков В.Ю., Мирошников В.М. Дифференцированный подход к лечению уратного нефролитиаза у больных различного возраста. Успехи современного естествознания. 2002;2:37-43. Ссылка активна на 07.07.2023. [Chichkov VYu, Miroshnikov VM. Differentiated approach to the treatment of urate nephrolithiasis in patients of different ages. Advances in Current Natural Sciences. 2002;2:37-43. (In Russ.).] https://natural-sciences.ru/ru/article/view?id=14070 10. Ejaz AA, Nakagawa T, Kanbay M, Kuwabara M, Kumar A, Garcia Arroyo FE, Roncal-Jimenez C, Sasai F, Kang DH, Jensen T, Hernando AA, Rodriguez-Iturbe B, Garcia G, Tolan DR, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ. Hyperuricemia in kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage. Seminars in Nephrology. 2020;40(6):574-585. DOI: 10.1016/j.semnephrol.2020.12.004 11. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-452. DOI: 10.1038/nature742 12. Барскова В.Г., Мукагова М.В. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Современенная ревматология. 2011;5(4):39-43. [Barskova VG. Mukagova MV. Current ideas on the pathogenesis of uric acid nephrolithiasis and its correction methods in gouty patients. Modern Rheumatology Journal. 2011;5(4):39-43. (In Russ.).] DOI: 10.14412/1996-7012-2011-696 13. Khashayar S. Recent advances in the pathophysiology of nephrolithiasis. Kidney International. 2009;75(6):585-595. DOI: 10.1038/ki.2008.626 14. Li H, Klett DE, Littleton R, Elder JS, Sammon JD. Role of insulin resistance in uric acid nephrolithiasis. World Journal of Nephrology. 2014;3(4):237-242. DOI:10.5527/wjn.v3.i4.237 15. Gromova M, Tsurko V, Kashkadayeva A, Averinova S, Aliokhin A. Assessment of the kidneys and urinary tract dysfunctions that increase the risk of developing chronic kidney disease in patients with gout based on complex renal scintigraphy. Annals of the Rheumatic Diseases. 2019;78(Suppl. 2):1903-1904. DOI: 10.1136/annrheumdis-2019-eular.755 16. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nature Reviews Rheumatology. 2014;10(11):654-661. DOI: 10.1038/nrrheum.2014.124 17. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension. 2015;33(9):1729-1741. DOI: 10.1097/hjh.0000000000000701 18. Jing J, Kielstein JT, Schultheiss UT, Sitter T, Titze SI, Schaeffner ES, McAdams-DeMarco M, Kronenberg F, Eckardt KU, Köttgen A; GCKD Study Investigators. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrology, Dialysis, Transplantation. 2015;30(4):613-662. DOI: 10.1093/ndt/gfu352 19. Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang H.C, Chiou MJ. Risk of endstage renal disease associated with gout: a nationwide population study. Arthritis Research & Therapy. 2012;14(2):R83. DOI: 10.1186/ar3806 20. Geiderman JM. An elderly woman with a warm, painful finger. Western Journal of Medicine. 2000;172(1):51-52. DOI: 10.1136/ewjm.172.1.51 21. Цурко В.В., Елисеева М.Е., Воробьев П.А. Особенности течения подагры в пожилом возрасте. Терапевтический архив. 2014;86(5):50-55. Ссылка активна на 07.07.2023. [Tsurko VV, Yeliseyeva ME, Vorobyov PA. Specific features of gout in the elderly. Therapeutic Archives. 2014;5(86):50-55. (In Russ.).] https://ter-arkhiv.ru/0040-3660/issue/view/1787 22. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephr1olithiasis: meta-analysis of observational studies. Arthritis Research & Therapy. 2015;17(1):90. DOI: 10.1186/s13075-015-0610-9 23. Umekawa T, Chegini N, Khan SR. Increased expression of Monocyte Chemoattractant Protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrology, Dialysis, Transplantation. 2003;18(4):664-669. DOI: 10.1093/ndt/gfg140 24. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrology. 2014;15:122. DOI: 10.1186/1471-2369-15-122 25. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O’Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RP, Brown MJ, Gaffo AL, Pirastu N, Li G, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, Liu X, Malerba G, Lopez LM, van der Harst P, Li X, Kleber ME, Hicks AA, Nolte IM, Johansson A, Murgia F, Wild SH, Bakker SJ, Peden JF, Dehghan A, Steri M, Tenesa A, Lagou V, Salo P, Mangino M, Rose LM, Lehtimäki T, Woodward OM, Okada Y, Tin A, Müller C, Oldmeadow C, Putku M, Czamara D, Kraft P, Frogheri L, Thun GA, Grotevendt A, Gislason GK, Harris TB, Launer LJ, McArdle P, Shuldiner AR, Boerwinkle E, Coresh J, Schmidt H, Schallert M, Martin NG, Montgomery GW, Kubo M, Nakamura Y, Tanaka T, Munroe PB, Samani NJ, Jacobs DR Jr, Liu K, D’Adamo P, Ulivi S, Rotter JI, Psaty BM, Vollenweider P, Waeber G, Campbell S, Devuyst O, Navarro P, Kolcic I, Hastie N, Balkau B, Froguel P, Esko T, Salumets A, Khaw KT, Langenberg C, Wareham NJ, Isaacs A, Kraja A, Zhang Q, Wild PS, Scott RJ, Holliday EG, Org E, Viigimaa M, Bandinelli S, Metter JE, Lupo A, Trabetti E, Sorice R, Döring A, Lattka E, Strauch K, Theis F, Waldenberger M, Wichmann HE, Davies G, Gow AJ, Bruinenberg M; LifeLines Cohort Study; Stolk RP, Kooner JS, Zhang W, Winkelmann BR, Boehm BO, Lucae S, Penninx BW, Smit JH, Curhan G, Mudgal P, Plenge RM, Portas L, Persico I, Kirin M, Wilson JF, Leach IM, van Gilst WH, Goel A, Ongen H, Hofman A, Rivadeneira F, Uitterlinden AG, Imboden M, von Eckardstein A, Cucca F, Nagaraja R, Piras MG, Nauck M, Schurmann C, Budde K, Ernst F, Farrington SM, Theodoratou E, Prokopenko I, Stumvoll M, Jula A, Perola M, Salomaa V, Shin SY, Spector TD, Sala C, Ridker PM, Kähönen M, Viikari J, Hengstenberg C, Nelson CP; CARDIoGRAM Consortium; DIAGRAM Consortium; ICBP Consortium; MAGIC Consortium; Meschia JF, Nalls MA, Sharma P, Singleton AB, Kamatani N, Zeller T, Burnier M, Attia J, Laan M, Klopp N, Hillege HL, Kloiber S, Choi H, Pirastu M, Tore S, Probst-Hensch NM, Völzke H, Gudnason V, Parsa A, Schmidt R, Whitfield JB, Fornage M, Gasparini P, Siscovick DS, Polašek O, Campbell H, Rudan I, Bouatia-Naji N, Metspalu A, Loos RJF, van Duijn CM, Borecki IB, Ferrucci L, Gambaro G, Deary IJ, Wolffenbuttel BHR, Chambers JC, März W, Pramstaller PP, Snieder H, Gyllensten U, Wright AF, Navis G, Watkins H, Witteman JCM, Sanna S, Schipf S, Dunlop MG, Tönjes A, Ripatti S, Soranzo N, Toniolo D, Chasman DI, Raitakari O, Kao WHL, Ciullo M, Fox CS, Caulfield M, Bochud M, Gieger C. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nature Genetics. 2013;45(2):145-154. DOI: 10.1038/ng.2500 26. Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. The American Journal of Medicine. 2012;125(5):499-504. DOI: 10.1016/j.amjmed.2011.11.010 27. Richette P, Clerson P, Périssin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Annals of the Rheumatic Diseases. 2015;74(1):142-147. DOI:10.1136/annrheumdis-2013-203779 28. Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, Deltas C, Hosking A, Kmoch S, Rampoldi L, Wiesener M, Wolf MT, Devuyst О; Kidney Disease: Improving Global Outcomes. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management – a KDIGO consensus report. Kidney International. 2015;88(4):676-683. DOI: 10.1038/ki.2015.28 29. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford, England). 2009;48(Suppl. 2):ii2-ii8. DOI: 10.1093/rheumatology/kep086 30. Döring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, Paulweber B, Pfeufer A, Rosskopf D, Völzke H, Illig T, Meitinger T, Wichmann HE, Meisinger C. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics. 2008;40(4):430-436. DOI: 10.1038/ng.107 31. Testa A, Mallamaci F, Spoto B, Pisano A, Sanguedolce MC, Tripepi G, Leonardis D, Zoccali C. Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clinical Journal of the American Society of Nephrology. 2014;9(6):1059-1065. DOI: 10.2215/cjn.11041013 32. Dalbeth N, Merriman TR, Stamp LK. Gout. The Lancet. 2016;388(10055):2039-2052. DOI: 10.1016/S0140-6736(16)00346-9 33. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2017;76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707 34. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care & Research. 2020;72(6):744-760. DOI: 10.1002/acr.24180 35. Воробьев П.А., Цурко В.В., Елисеева М.Е. Подагра в гериатрической практике (Методические рекомендации. Часть I). Клиническая геронтология. 2016;3-4(22):3-9. Ссылка активна на 07.07.2023. [Vorobyov PA, Tsurko VV, Yeliseyeva ME. Gout in geriatric practice (Guidelines. Part I). Clinical Gerontology. 2016;3-4(22):3-9. (In Russ.).] http://publish.newdiamed.ru/arhive/kg03_0416_web.pdf 36. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis & Rheumatism. 2010;62(4):1060-1068. DOI: 10.1002/art.27327 37. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Database of Systematic Reviews. 2014 Sep;(9):CD010120. DOI: 10.1002/14651858.cd010120.pub2 38. Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LSh, Choi YF, Yau WH, Lee KH, Graham CA. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Annals of Internal Medicine. 2016;164(7):464-471. DOI: 10.7326/m14-2070 39. Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clinical Drug Investigation. 2014;34(12):845-855. DOI: 10.1007/s40261-014-0238-6 40. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides, Nucleotides & Nucleic Acids. 2008;27(6):585-591. DOI: 10.1080/15257770802136032 41. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel P LCM, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. The Lancet. 2008;371(9627):1854-1860. DOI: 10.1016/s0140-6736(08)60799-0 42. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. The Cochrane Database of Systematic Reviews. 2013 Apr;(4):CD009920. DOI: 10.1002/14651858.cd009920.pub2 43. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LAG. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50:973-981. DOI: 10.1093/rheumatology/keq363 44. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clinical Therapeutics. 2010;32(14):2386-2397. DOI: 10.1016/j.clinthera.2011.01.008 45. Fuldeore MJ, Riedel AA, Zarotsk V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrology. 2011;12:36-41. DOI: 10.1186/1471-2369-12-36 46. Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health study. Annals of the Rheumatic Diseases. 2012;71(6):924-928. DOI: 10.1136/ard.2011.200523 47. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and diet: a comprehensive review of mechanisms and management. Nutrients. 2022;14(17):3525. DOI: 10.3390/nu14173525 48. Громова М.А., Цурко В.В., Мелехина А.С. Рационально-обоснованный подход к питанию у больных подагрой. Клиницист. 2019;13(3-4):15-21. [Gromova MA, Tsurko VV, Melekhina AS. Rational approach to nutrition for patients with gout. The Clinician. 2019;13(3-4):15-21. (In Russ.).] DOI: 10.17650/1818-8338-2019-13-3-4-15-21 49. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. Journal of the American Academy of Dermatology. 2008;58:25-32. DOI: 10.1016/j.jaad.2007.08.036 50. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. American Journal of Kidney Diseases. 2015;66(6):945-950. DOI: 10.1053/j.ajkd.2015.05.017 51. Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis & Rheumatology (Hoboken, N.J.). 2016;68(8):2035-2043. DOI: 10.1002/art.39654 52. Yang CY, Chen CH, Deng ST, Huang CS, Lin YJ, Chen YJ, Wu CY, Hung SI, Chung WH. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Internal Medicine. 2015;175(9):1550-1557. DOI: 10.1001/jamainternmed.2015.3536 53. Neogi T, Dalbeth N, Stamp L, Castelar G, Fitzgerald J, Gaffo A, Mikuls TR, Singh J, Vázquez-Mellado J, Edwardset NL. Renal dosing of allopurinol results in suboptimal gout care. Annals of Rheumatic Diseases. 2017;76(1):e1. DOI: 10.1136/annrheumdis-2016-210352 54. Richette P, Doherty M, Pascual E, Bardin T. Response: renal dosing of allopurinol results in suboptimal gout care by T. Neogi et al. Annals of the Rheumatic Diseases. 2017;76(1):e2. DOI: 10.1136/annrheumdis-2016-210356    [ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]